Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study

Eric Van Cutsem, Maria Di Bartolomeo, Elizabeth Smyth, Ian Chau, Haeseong Park, Salvatore Siena, Sara Lonardi, Zev A. Wainberg, Jaffer A. Ajani, Joseph Chao, Yelena Y. Janjigian, Amy Qin, Jasmeet Singh, Ferdous M. Barlaskar, Yoshinori Kawaguchi, Geoffrey Y. Ku